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AbsTRACT
background: It was hypothesized that the observed slight immunostimula-
tory effect of the 23-valent pneumococcal polysaccharide (pneumo-23) vaccine might 
be due to the presence of low levels of zwitterionic motifs. Therefore, it was hypothe-
sized further that introducing zwitterionic motifs experimentally into polysaccharides 
of pneumo-23 vaccine might render it an effective immunostimulatory agent.
Objective: This study was conducted to assess the in vitro immunostimulatory 
effect of zwitterionized pneumo-23 (Z-P23) vaccine compared with the nonzwitterion- 
ized commercial pneumo-23 (C-P23) vaccine.
Methods: In vitro proliferation, ELISA-based in vitro cytokine synthesis (inter-
leukin [IL]-2, interferon [IFN]-γ, and IL-10), and immunofluorescence microscopy-
based immune cell profiling (CD4+, CD8+, and CD21+ cells) assays were used to 
evaluate the immunostimulatory effect of Z-P23 on peripheral blood mononuclear 
cells (PBMC) of immunosuppressed cancer (IC) patients and healthy control subjects 
in comparison with PBMC exposed to C-P23, concanavalin A (positive control), and 
phosphate-buffered saline (PBS) (negative control).
Results: Z-P23 induced proliferation of PBMC in the IC (81.1%) and control 
(75.1%) groups significantly higher than that achieved with concanavalin A in the IC 
group (51.0%; P = 0.01) but not in the control group (89.2%; P = NS). This was also 
significantly higher than that achieved with C-P23 in the IC (4.8%; P < 0.001) and 
control (6.2%; P < 0.001) groups. Z-P23 induced IL-2 and IFN-γ synthesis in the IC 
group (0.61 and 0.45 ng/mL, respectively) significantly more than that with C-P23 
(0.4 and 0.45 ng/mL; P = 0.002 and P <0.001), concanavalin A (0.45 and 0.31 ng/mL; 
P = 0.021 and P = 0.03), and PBS (0.41 and 0.29 ng/mL; P = 0.005 and P = 0.04) 
but not the control group. Z-P23 induced expansion of CD4+, CD8+, and CD21+
lymphocytes (39.3%, 42.7%, and 8.1%, respectively) in the IC group higher than 
that with C-P23 (28.3%, 30.1%, and 5.5%; P = 0.01, P = 0.003, and P = NS), con-
canavalin A (27.2%, 35.8%, and 4.1%; P = 0.02, P = 0.048, and P = 0.035), and 
PBS (25.6%, 31.9%, and 4.2%; P = 0.018, P = 0.02, and P = 0.045).
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Conclusion: The in vitro immunostimulatory potential of Z-P23 was clearly 
observed on PBMC of IC patients as well as, to a lesser extent, healthy control subjects, 
stimulating the synthesis of core cytokines of T-helper 1, and primarily inducing 
CD4+ and CD8+T cells. (Curr Ther Res Clin Exp. 2010;71:60–78) © 2010 Excerpta 
Medica Inc.
Key words: polyvalent pneumococcal vaccine, pneumo-23, zwitterionic, cancer, 
immunostimulatory, immune suppression.
InTROduCTIOn
The 23-valent pneumococcal polysaccharide vaccine (pneumo-23) was primarily 
designed to confer immunity against severe pneumococcal infections in elderly pa-
tients and those who undergo splenectomy as part of a management of various hema-
tologic disorders,1,2 rendering these patients unsusceptible to the development of 
overwhelming sepsis by Streptococcus pneumoniae.1–4 It is a clear, colorless liquid pre-
pared from purified pneumococcal capsular antigens. Each dose of 0.5 mL contains 
purified S pneumoniae polysaccharides; 25 µg of each includes 23 serotypes.1,2 Al-
though pneumo-23 is composed of non–T cell-dependent polysaccharides, it has been 
observed that, when administered to elderly people or immunosuppressed patients, 
their immune response, with unexplained etiology, was moderately enhanced nonspe-
cifically in addition to the immune protection achieved against pneumococcal 
infection.1,4 There are also reports of nonspecific and generalized immunostimulation 
with protective effects against microbes other than pneumococci with pneumo-23.1,4–7
One study suggested that the pneumo-23 vaccine enhanced opsonization and sus-
tained normal compliment components of C3 and C4 in elderly cancer patients after 
splenectomy.5 Moreover, recent studies suggest that the majority of pneumo-23 poly-
saccharides are T cell–independent substances. The small portion (serotype 1) that are 
not have T cell–dependent zwitterionic motifs that possess toll-like receptor (TLR) 
ligands by which it might be responsible for inducing T cell–dependent im- 
munity.6,7 Unlike most bacterial polysaccharides, which are anionic/neutral T cell– 
independent, zwitterionic polysaccharides possess both positive and negative ions. 
They have been found to trigger in vitro T cell–dependent immune response, initiate 
class switching and affinity maturation of immunoglobulins, and induce long-term 
memory immunity.6–9 In addition, it was revealed that the protection of pneumo-23 
vaccine after splenectomy was remarkable against the sepsis of many bacteria other 
than pneumococci, indicating a possible role of the nonspecific immunostimulatory 
effect of pneumo-23 vaccine.5
Accordingly, it was hypothesized that the observed slight immunostimulatory ef-
fect of the commercial pneumo-23 (C-P23) might be due to the presence of low levels 
of zwitterionic motifs. Therefore, it was hypothesized further that introducing zwit-
terionic motifs experimentally into polysaccharides of pneumo-23 vaccine might 
render it an effective immunostimulatory agent. In the present study, polysaccharides 
of the C-P23 were modified chemically by adding zwitterionic motifs, creating zwit-
terionized pneumo-23 (Z-P23). A search of the literature was conducted in the Scopus 
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and ScienceDirect databases and of Google (2006–2009) using the following terms: 
pneumo-23, P-23, zwitterionisation, immunosuppression, and immunostimulation. The search 
found no published study that assessed the immunostimulatory effects of zwitterion- 
ized polysaccharides of pneumo-23.
pATIenTs And MeThOds
study population
Because the target population of immunostimulatory agents is immunosuppressed 
patients, the ability of Z-P23 vaccine to trigger T cell–dependent immunostimulatory 
effect was targeted against immunosuppressed cancer (IC) patients. However, healthy 
control subjects were involved as a comparator factor to explore the ability of the re-
sulting immunostimulatory effect of Z-P23, if any, to modulate different levels of 
functionality of immune systems. 
Cancer and the associated chemotherapy are considered ideal for immunosuppres-
sion; therefore, 3 kinds of common cancers in Southeast Asia were involved in this 
study (ie, lung, head and neck, and colorectal cancers). This study was conducted in 
the period from November 2006 to February 2009 at 3 hospitals in Malaysia (Hospi-
tal Serdang, Selangor; Hospital Kajang, Selangor; and Hospital Kuala Lumpur, Kuala 
Lumpur). The evaluation of patients and controls was conducted by oncologist spe-
cialists, a member of the study team (F.A.), medical specialists, and medical laboratory 
specialists. To meet the inclusion and exclusion criteria of the present study, patients 
were examined for other diseases; diagnostic tests were performed and full medical, 
surgical, and drug intake history was assessed. The inclusion criteria of the involved 
cancer patients were as follows: confirmed diagnosis of advanced cancer (stages III and 
IV); preoperative; immunosuppressed; engaged regularly in chemotherapy; and a 
minimum of 6 weeks’ interval from the last chemotherapy. The selection was done 
without any bias to the type of cancer involved. The exclusion criteria were as follows: 
immunocompetent patients; early stage of disease; administration of immunostimula-
tory medicines or supplements; concurrent allergic or major medical illness; concur-
rent autoimmune disease; malnutrition; and previous exposure to pneumococcal vac-
cine. The immunosuppression of involved patients was defined as compromised immune 
defense mechanisms measured in both clinical and laboratory tests. Therefore, pa-
tients were defined as immunosuppressed when they showed abnormally high suscep-
tibility to frequent infections, lymphopenia via complete blood count, and a state of 
hypo-γ-globulinemia, with serum immunoglobulin (Ig) G <250 mg/dL, and serum 
IgA <5 mg/dL. The immunosuppression status of involved patients was rechecked 
and confirmed by a second level of scrutiny: the immunologic assays conducted in the 
present study. Therefore, any case that was found not fit for the definition of immu-
nosuppression by either clinical/laboratory tests or the present study’s immunologic 
assays was then excluded.
Age- and sex-matched healthy volunteers were recruited from hospital outpatients 
for minor trauma. The volunteers were all assessed similarly by relevant medical and 
surgical specialists; a thorough medical examination was conducted and their medical 
records were reviewed. The inclusion criteria were as follows: normal general health; 
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and normal blood and biochemical laboratory tests (eg, erythrocyte sedimentation 
rate, complete blood count, liver function test, kidney function tests, and total serum 
proteins). In addition, normal chest x-ray, normal barium enema radiograms, normal 
colonoscopy, and thorough clinical examination of the throat were conducted to exclude 
cancer conditions; suspected cases of colorectal cancer were subjected to colonoscopy. 
Exclusion criteria were as follows: present or previous major illness; history of cancer; 
present cancer; administration of immunosuppressive drugs; administration of im-
munostimulatory supplements; malnutrition; stress; pregnancy; and previous expo-
sure to pneumococcal vaccine. 
Blood samples were drawn from both groups after obtaining written informed 
consent. Withdrawn blood was stored at 4°C in heparinized tubes for later isolation 
of peripheral blood mononuclear cells (PBMC). Permission to conduct this study was 
granted from the regional committee of ethics for biomedical research.
Zwitterionization of pneumo-23 polysaccharides
Chemical modification of polysaccharides of the C-P23* was done by adding 
positively charged motifs to convert polysaccharides to zwitterionic polysaccharides. 
The procedure of zwitterionization was done according to Gallorini et al.6 Briefly, a 
chemical oxidation of the aliphatic chain from the terminal N-acetylneuraminic 
acid (NeuNAc) residue using 0.01 M sodium metaperiodate (NaIO4; Sigma- 
Aldrich, St. Louis, Missouri) for 90 minutes at room temperature was conducted, 
leaving an aldehyde group. NaIO4 was used as a limiting (30%) or stoichiometric 
(100%) reagent of the reaction. The periodate oxidation selectively cleaves the 
C8–C9 bond between vicinal hydroxyl groups (–CHOH–CH2OH) of NeuNAc resi-
dues, leaving an aldehyde group (–CHO) at C8. This group was converted to a 
cationic ammonia group (–NH3
+) by reductive amination using 300 mg/mL am-
monium acetate (NH4Ac) (Sigma-Aldrich) and 49 mg/mL sodium cyanoborohy-
dride (NaBH3CN) (Sigma-Aldrich) at pH 6.5 for 5 days at 37°C. The polysaccha-
rides obtained (R-CH2NH2) were treated with 37% formaldehyde (Merck KGaA, 
Darmstadt, Germany) in the presence of NaBH3CN to convert the generated free 
amino group to a tertiary dimethylamine (R-CH2NH[CH3]2
+) such that it retained 
a positive charge. This conversion was confirmed by the routine application 
of nuclear magnetic resonance (NMR) spectroscopy (Avance 600, Bruker BioSpin, 
Rheinstetten, Germany) using a 5-mm triple-resonance NMR probe as evidenced 
by the resonance at 2.9 ppm. The NMRShiftDB open-source software was used for 
processing the data obtained. The content of Z-P23 and C-P23 was measured us-
ing the colorimetric anthrone method10; glucose was used as a standard and the 
absorbance was measured at 625 nm. This method was found to be the most precise 
for measuring modified polysaccharides due to the fact that it determined both re-
ducing and nonreducing sugars because of the presence of the strongly oxidizing 
sulfuric acid.
*Trademark: Pneumo 23® (Sanofi Pasteur, Lyon, France).
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positive and negative Controls
Because recent studies found that concanavalin A is one of the most potent TLR-
dependent immunostimulating factors11,12 mimicking the most probable mechanism of 
immunostimulation of zwitterionic polysaccharides, it was used in the current study as the 
positive control immunostimulatory agent. Phosphate buffered saline (PBS) was used as 
the negative control as it has no active ingredient for stimulating immune cells. 
The strategy of Conducting In Vitro Assays
The in vitro PBMC challenge with Z-P23, C-P23, PBS, and concanavalin A, in vitro 
proliferation assay, in vitro PBMC cytokine synthesis assay, and in vitro peripheral blood 
lymphocytes (PBL) subset marking assay were all conducted blindly by 2 researchers; the 
first, a study investigator (A.S.A.), and the second, an independent nonstudy investigator. 
This strategy was necessary to ensure the fidelity of the findings of the present pilot study.
Isolation of peripheral blood Mononuclear Cells
Isolation of PBMC from heparinized whole blood of IC patients and control sub-
jects was conducted to prepare a population of cells containing T and B lymphocytes 
for the subsequent in vitro assays. PBMC separation was carried out in an ultraviolet 
hood. The procedure was based on the gradient density sedimentation technique in-
volving Ficoll Hypaque (Sigma-Aldrich).13 Cell viability for every separation was 
done and >99% of cells were found viable. Final concentration of the isolated PBMC 
suspension was adjusted to 1 × 106 cells/mL.
pbMC Challenge With Z-p23, C-p23, pbs, and Concanavalin A
One hundred µL of PBMC suspension (1 × 106 cells/mL) in complete Roswell Park 
Memorial Institute (RPMI)–1640 medium (Merck KGaA) with 200 U/mL penicillin 
G (Sigma-Aldrich), 200 µg/mL streptomycin (Merck KGaA), and 10% human AB 
serum (BDH Prolabo, Leicester, United Kingdom) were added to 96-well microtiter 
plates in duplicates. Initially, cells were cultured for 1 day in a humid sterile incuba-
tor; then, 10 µL of 40 µg/mL concanavalin A mitogen was added as the positive con-
trol; 10 µL of 5 µg/mL of Z-P23 or C-P23 diluted in PBS were added as test samples; 
and 10 µL of PBS alone was added as the negative control. The concentration of Z-P23 
and C-P23 (5 µg/mL) was determined after many standardization trials. PBMC in 
complete RPMI-1640 medium was incubated with Z-P23, C-P23, PBS, and conca-
navalin A for 48 hours at 37°C. Afterwards, PBMC was subjected to 3 in vitro assays; 
3-(4,5,dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide micro- 
culture (MTT) assay (Sigma-Aldrich) to measure the proliferative potential of PBMC; 
ELISA for in vitro synthesis of PBMC cytokines (interleukin [IL]-2, interferon [IFN]-γ, 
and IL-10); and PBL subset profiling (CD4+, CD8+, and CD21+).
In Vitro proliferative Assay
After 48 hours of PBMC incubation with Z-P23, C-P23, PBS, and concanavalin A, 
40 µL of the MTT reagent at 5 mg/mL were added to the microtiter plate and incu-
bated for 4 hours at 37°C. Finally, the supernatant was removed by Pasteur pi-
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pette and 100 µL of isopropanol was added. An ELISA reader (Bio-Rad Laboratories, 
Inc., Hercules, California) was used to measure the optical density at 540 nm.14 By 
using the MTT assay, the proliferative activity of living PBMC exposed to mito-
genic substances was measured.15 The proliferative percentage of the challenged 
PBMC with Z-P23, C-P23, and concanavalin A was calculated in relation to the 
negative control, PBS, according to the following equation16:
Proliferative % = (absorbency of experimental wells/absorbency  
of negative control wells) – 1 × 100.
eLIsA for In Vitro synthesis of pbMC Cytokines
After 48 hours of PBMC incubation with Z-P23, C-P23, concanavalin A, and PBS, the 
PBMC were centrifuged at 3000g for 5 minutes and the supernatant was withdrawn. After 
a series of standardization steps, mouse monoclonal antihuman IL-2, IFN-γ, and IL-10 
capturing antibodies (Dako Denmark A/S, Glostrup, Denmark) were diluted at 1:10 in a 
carbonate-bicarbonate coating buffer (1.59 g/L carbonate and 2.93 g/L bicarbonate; Sigma- 
Aldrich) at a final concentration of 0.1 mg/mL. Fifty µL/well of the diluted capturing 
antibodies in coating buffer were added and incubated overnight at 4°C. On the following 
day, 50 µL/well of the supernatant diluted at 1:4 in blocking buffer (bovine serum albu-
min; Sigma-Aldrich) were added in duplicates and the microtiter plate was incubated for 
1 hour at 37°C. Horseradish-peroxidase (HRP)–labeled rabbit monoclonal antihuman 
IL-2, IFN-γ, and IL-10 antibodies (ICN Immunologicals, High Wycombe, United King-
dom) were diluted at 1:100 in the antibody dilution buffer (ICN Immunologicals) at a 
final concentration of 0.01, 0.005, and 0.0005 mg/mL, respectively. After a washing step, 
50 µL/well of the diluted HRP-labeled rabbit monoclonal antihuman IL-2, IFN-γ, and 
IL-10 antibodies were added and incubated for 1 hour at 37°C. The conjugated antibodies 
recognize different epitopes in IL-2, IFN-γ, and IL-10 from those recognized by the cap-
turing antibodies. After a washing step, 50 µL/well of ortho-phenylenediamine hydrogen 
peroxide as chromogen-substrate (Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France) 
were added for 20 minutes at 37°C. For each run, duplicate wells of the negative control 
of the run were used by adding antibody dilution buffer alone instead of monoclonal 
antibodies. ELISA readings in terms of optical density were measured at wavelength 
492 nm.17 A series of standards for IL-2, IFN-γ, and IL-10 (Sigma-Aldrich) were used to 
obtain the linear regression analysis of the resultant standard curve. Moreover, the median 
value of the standard curve was considered as the positive control of the ELISA run. The 
achieved correlation coefficient of the standard curve was 0.81, which indicated a high 
linear behavior of the customized ELISA. The minimal detection limits for IL-2, IFN-γ, 
and IL-10 were 0.1, 0.08, and 0.1 ng/mL, respectively.
Immune phenotyping via direct Immune Fluorescence Microscopy
Fixation of PBMC Cells
After 48 hours of incubation with Z-P23, C-P23, concanavalin A, and PBS, the 
PBMC were centrifuged at 3000g for 5 minutes and the pellet was resuspended in 
PBS. Fifteen microliters of PBMC suspension (1 × 106 cells/mL) were placed onto cir-
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cular depressions of the immunofluorescence slides. Slides were allowed to dry for 
~1 to 2 hours. Fifteen microliters of fixative solution (buffered formal acetone com-
posed of 5.7% v/v PBS, 24% v/v 40% formalin, and 43% v/v acetone; Merck KGaA) 
were added per depression to cover all the dried lymphocytes, and the slides were 
stored at –20°C for later use.18
Fluorescent Microscopy
Fifteen microliters of immunofluorescence-labeled monoclonal antibodies (ie, anti-
CD4, anti-CD8, and anti-CD21; Dako Denmark A/S) were diluted at 1:5 in anti-
body dilution buffer (Dako Denmark A/S) to final concentrations of 0.1, 0.1, and 
0.05 mg/mL, respectively. These antibodies were placed onto slide depressions in 
duplicates for 1 hour at 37°C with mild shaking. After dipping and stirring the slides 
in a PBS-filled jar for 10 minutes, 1 to 2 drops of mounting fluid were added. After 
adding coverslips, examination of the slides was conducted under immunofluorescent 
microscope at 40× and 100× magnification. At the light microscopy phase, a suitable 
countable field was chosen to count the total number of lymphocytes. At the ultravio-
let light phase, only the fluorescently stained cells were counted. The average percent-
age of the fluorescently stained cells was calculated from the total PBL in 5 high-
power fields multiplied by 100.19
statistical Analysis
The statistical analysis was performed using SPSS version 10 (SPSS Inc., Chicago, 
Illinois) and Excel 2000 (Microsoft Corporation, Redmond, Washington). Kolmogorov-
Smirnov tests were used to confirm the normal distribution pattern of MTT, ELISA, and 
immunofluorescent CD marking values. Mean (SEM) of the averaged values, pairwise 
parametric multivariate t tests, and single-factor ANOVA tests were used to evaluate 
significant differences. P < 0.05 was considered statistically significant.
ResuLTs
A total of 94 cancer patients volunteered for this study. However, 29 of the 94 cancer pa-
tients did not match the required level of immunosuppression. Therefore, 65 IC patients 
(age range, 42–62 years) were enrolled in this study including 42 men with lung (n = 22), 
head and neck (n = 11), and colorectal (n = 9) cancers and 23 women with lung (n = 13), 
colorectal (n = 7), and head and neck (n = 3) cancers. A total of 100 volunteers (age range, 
40–65 years) were recruited and enrolled in the healthy control group.
demographic Characteristics and baseline  
Immunity-Assessment Tests
The demographic characteristics including age, sex, and the key immune-assessment 
laboratory tests of the involved IC and control groups are shown in the table.
In Vitro proliferative Assay
The mean (SEM) proliferative percentage of PBMC of IC patients exposed to Z-P23 
(81.1% [7.6%]) was similar to that in the control group (75.1% [8.4%]) (Figure 1). 
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Table.  Demographic characteristics and basic immune-evaluating blood tests in the studied immunocompromised cancer and 
healthy control groups. All data are mean (SEM) unless otherwise noted.
  Head and Colorectal 
 All Cancer Lung Cancer Neck Cancer Cancer Control 
Variable (n = 65) (n = 35) (n = 14) (n = 16) (n = 100)
Age, y 56.5 (6.3) 56.9 (6.2) 54.3 (4.9) 56.1 (5.9) 57.3 (3.1)
Sex ratio, male:female 1.8:1 1.7:1 3.6:1 1.3:1 1.77:1
Lymphopenia, cells/µL 760.4 (44.3) 748.1 (42.8) 471.2 (31.4) 1041 (59.7) 3963.4 (85.4)
Serum IgG, mg/dL 100.3 (12.1) 116.5 (13.6) 63.7 (8.9) 97.8 (11.5) 1145.0 (25.7)
Serum IgA, mg/dL 1.9 (0.5) 2.1 (0.5) 1.5 (0.6) 1.9 (0.3) 96.7 (26.9) 
Ig = immunoglobulin.
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The proliferative percentage of concanavalin A in the IC group (51.0% [8.9%]) was 
significantly lower than that in the control group (89.2% [9.6%]; P = 0.001). Ac-
cordingly, the proliferative percentage of Z-P23 in the IC group was significantly 
higher than that driven by concanavalin A in the IC group (P = 0.01), while the pro-
liferative percentage of Z-P23 in the control group was not significantly different 
from that driven by concanavalin A. The proliferative percentage of C-P23 in the IC 
group (4.8% [1.4%]) and in the control group (6.2% [1.6%]) was significantly lower 
than that of Z-P23 in both groups as well as the proliferative percentage of concanava-
lin A in both groups (all, P < 0.001). Consequently, Z-P23 induced a remarkable 
proliferation in both immunosuppressed and, to a lesser extent, immunocompetent 
groups while concanavalin A induced proliferation mainly in the immunocompetent 
group rather than the immunosuppressed group.
In Vitro synthesis of Cytokines
ELISA for in vitro synthesis of cytokines was conducted on PBMC of both the IC 
and control groups and divided into 4 subgroups: Z-P23, C-P23, PBS (negative con-
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Figure 1.  The calculated proliferative percentages of peripheral blood mononuclear cells 
in immunosuppressed cancer (IC) patients and immunocompetent healthy con-
trols (HC) in response to zwitterionized 23-valent pneumococcal polysaccharide 
vaccine (Z-P23), nonzwitterionized commercial 23-valent pneumococcal poly-
saccharide vaccine (C-P23), and concanavalin A measured by tetrazolium bro-
mide microculture assay.
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trol), and concanavalin A (positive control) where PBMC were exposed for 48 hours 
to Z-P23, C-P23, PBS, and concanavalin A, respectively (Figure 2). In the IC group, 
it was found that the mean synthesis of soluble IL-2 (0.61 [0.06] ng/mL) and IFN-γ 
(0.45 [0.052] ng/mL) in PBMC exposed to Z-P23 was significantly higher than that 
exposed to PBS (0.41 [0.03] and 0.29 [0.051] ng/mL; P = 0.005 and P = 0.04, re-
spectively), C-P23 (0.40 [0.02] and 0.27 [0.01] ng/mL; P = 0.002 and P < 0.001), 
and concanavalin A (0.45 [0.03] and 0.31 [0.03] ng/mL; P = 0.021 and P = 0.03). 
ANOVA of IL-2 and IFN-γ levels among C-P23, PBS, and concanavalin A groups showed 
that there were no significant differences between them. The mean synthesis of soluble 
IL-10 exposed to Z-P23 (0.36 [0.04] ng/mL), C-P23 (0.39 [0.02] ng/mL), PBS (0.40 
[0.04] ng/mL), and concanavalin A (0.42 [0.03] ng/mL) was not significantly different.
PBMC exposed to concanavalin A had significantly higher mean (SEM) IL-2 synthe-
sis (0.82 [0.04] ng/mL) than with Z-P23 (0.67 [0.06] ng/mL; P = 0.04), C-P23 (0.61 
[0.03] ng/mL; P = 0.008), and PBS (0.62 [0.03] ng/mL; P = 0.013) (Figure 3). The 
level of IFN-γ synthesis by PBMC exposed to Z-P23 (0.52 [0.03] ng/mL), C-P23 (0.51 
[0.04] ng/mL), PBS (0.45 [0.03] ng/mL), and concanavalin A (0.47 [0.04] ng/mL) did 
not differ significantly. IL-10 in PBMC exposed to Z-P23 (0.41 [0.03] ng/mL) was 
0.8
0.6
0
0.1
IL-2 IFN-γ IL-10
M
ea
n 
(S
EM
) 
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
0.4
0.2
Z-P23
C-P23
PBS
Concanavalin A
1.0
0.9
0.5
0.7
0.3
0.61
0.40 0.41
0.45
0.45
0.27
0.29 0.31
0.36 0.39
0.40 0.42
P = 0.002
P = 0.005
P = 0.021
P < 0.001
P = 0.04
P = 0.03
Figure 2.  Concentrations of the in vitro synthesis of interleukin (IL)-2, interferon (IFN)-γ, 
and IL-10 in peripheral blood mononuclear cells, from cancer patients, exposed 
for 48 hours to zwitterionized 23-valent pneumococcal polysaccharide vaccine 
(Z-P23), nonzwitterionized commercial 23-valent pneumococcal polysaccharide 
vaccine (C-P23), phosphate buffered saline (PBS), and concanavalin A.
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significantly higher than that in PBMC exposed to C-P23 (0.31 [0.01]; P = 0.02) and 
concanavalin A (0.36 [0.02] ng/mL; P = 0.048) but not significantly higher than in 
PBMC exposed to PBS (0.37 [0.05] ng/mL) (Figure 3). In addition, it is noteworthy 
to mention that there was no significant difference in the Z-P23–driven synthesis of 
IL-2, IFN-γ, and IL-10 in PBMC from the IC patients with respect to cancer type, 
age, and sex.
To clarify the behavior of Z-P23 and C-P23 in the IC group versus that in the 
control group, the magnitude of difference in cytokine synthesis by PBMC exposed to 
Z-P23 and C-P23 from that exposed to the negative control, termed synthesis upsurge, 
was used (Figure 4). The mean (SEM) synthesis upsurge of IL-2 and IFN-γ caused by 
Z-P23 in the IC group (0.21 [0.02] and 0.16 [0.03] ng/mL, respectively) was signifi-
cantly higher than that caused by Z-P23 in the control group (0.05 [0.02] and 0.07 
[0.03] ng/mL; P < 0.001 and P = 0.003). However, synthesis upsurge of IL-10 in 
Z-P23 in the IC group was negative (–0.04) or less than that in the negative control. 
Regarding C-P23, there was no synthesis upsurge for the studied cytokines observed 
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Figure 3.  Concentrations of the in vitro synthesis of interleukin (IL)-2, interferon (IFN)-γ, 
and IL-10 in peripheral blood mononuclear cells, from healthy controls, exposed 
for 48 hours to zwitterionized 23-valent pneumococcal polysaccharide vaccine 
(Z-P23), nonzwitterionized commercial 23-valent pneumococcal polysaccharide 
vaccine (C-P23), phosphate buffered saline (PBS), and concanavalin A.
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in both the IC and control groups; it was either negative or so shallow a synthesis 
upsurge that it could not be taken into consideration (Figure 4).
Immune phenotyping of Lymphocyte subsets
The immune phenotyping of PBL exposed to Z-P23, C-P23, PBS, and concanava-
lin A was assessed (Figure 5). Although the percentages of CD4+, CD8+, and CD21+
cells in the IC group were lower than those in the control group, the percentages were 
within the lowest tier of normal ranges; 30% to 60% for CD4+, 20% to 50% for 
CD8+, and 4% to 14% for CD21+ cells.14 In the IC group, the mean (SEM) percent-
ages of CD4+, CD8+, and CD21+ cells in the Z-P23 group (42.7% [3.2%], 39.3% 
[4.7%], and 8.1% [2.1%], respectively) were significantly higher than in the C-P23 
group (30.1% [2.2%], 28.3% [2.4%], and 5.5% [1.9%]; P = 0.003, P = 0.01, and 
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Figure 4.  Changes in cytokine concentrations in relation to the levels in the negative 
control (phosphate buffered saline) of interleukin (IL)-2, interferon (IFN)-γ, and 
IL-10 driven by zwitterionized 23-valent pneumococcal polysaccharide vaccine 
(Z-P23) and nonzwitterionized commercial 23-valent pneumococcal polysac-
charide vaccine (C-P23) in the immunocompromised cancer (IC) group versus 
the healthy control (HC) group.
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P = NS, respectively), PBS group (31.9% [4.1%], 25.6% [3.1%], and 4.2% [1.7%]; 
P = 0.02, P = 0.018, and P = 0.045), and concanavalin A group (35.8% [2.6%], 
27.2% [2.8%], and 4.1% [0.8%]; P = 0.048, P = 0.02, and P = 0.035). There was 
no significant difference found between the C-P23, PBS, and concanavalin A groups 
regarding the mean percentages of CD4+, CD8+, and CD21+.
In the control group, the only significant result was that concanavalin A raised 
the mean (SEM) percentages of CD4+ cells (51.6% [2.4%]) significantly greater 
than that of PBS (45.6% [3.1%]; P = 0.04) and C-P23 (41.6% [4.5%]; P = 0.006) 
but not significantly greater than that of Z-P23 (Figure 6). There was no signifi-
cant difference in the percentage of CD8+ cells among PBL exposed to Z-P23, 
C-P23, PBS, and concanavalin A (39.3% [4.2%], 37.8% [3.3%], 35.6% [2.6%], 
and 38.6% [2.7%], respectively), no significant difference in the percentages of 
CD4+ cells between PBL exposed to Z-P23, C-P23, and PBS, and no significant 
difference in the percentages of CD21+ cells between Z-P23, C-P23, PBS, and 
concanavalin A (8.3% [1.8%], 7.4% [2.0%], 7.8% [1.7%], and 7.6% [1.5%]). 
In addition, there was no significant difference in the Z-P23–driven percentages 
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Figure 5.  The mean percentages of peripheral blood lymphocytes (PBL) (CD4+, CD8+, and 
CD21+) in the peripheral blood mononuclear cells of cancer patients exposed 
for 48 hours to zwitterionized 23-valent pneumococcal polysaccharide vaccine 
(Z-P23), nonzwitterionized commercial 23-valent pneumococcal polysaccharide 
vaccine (C-P23), phosphate buffered saline (PBS), and concanavalin A.
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of CD4+, CD8+, and CD21+ cells in the IC group in respect to cancer type, age, 
and sex.
The magnitude of difference in CD4+, CD8+, and CD21+ cell percentage by PBMC 
exposed to Z-P23 and C-P23 from that exposed to negative control, termed PBL 
induction, was compared between the IC and control groups (Figure 7). CD4+, CD8+, 
and CD21+ induction by Z-P23 in the IC group (10.8% [1.6%], 13.7% [2.1%], and 
3.9% [1.3%], respectively) was significantly higher than that by Z-P23 in the control 
group (2.4% [1.1%], 3.7% [1.3%], and 0.5% [0.2%]; P < 0.001, P < 0.001, and 
P = 0.005, respectively), while PBMC exposed to C-P23 showed shallow or negative 
induction of PBL subsets and it was practicably negligible.
dIsCussIOn
The immunostimulatory effect of Z-P23 and C-P23 was tested on PBMC of IC pa-
tients in comparison with a healthy control group. We assessed the in vitro prolifera-
tive potential, the in vitro cytokine synthesis of IL-2, IFN-γ, and IL-10, and immune 
phenotyping (CD4+ as T-helper cells20; CD8+ as T-cytotoxic/suppressor cells20,21; and 
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Figure 6.  The mean percentages of CD4+, CD8+, and CD21+ cells in the peripheral blood 
mononuclear cells (PBMC) of healthy controls exposed for 48 hours to zwitteri-
onized 23-valent pneumococcal polysaccharide vaccine (Z-P23), nonzwitterion-
ized commercial 23-valent pneumococcal polysaccharide vaccine (C-P23), 
phosphate buffered saline (PBS), and concanavalin A.
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CD21+ as B cells21). We used the MTT assay for the in vitro proliferative assay,19,22
ELISA for in vitro cytokine synthesis, and direct immunofluorescence microscopy for 
immune phenotyping assays.
Unlike Z-P23, C-P23 did not show significant in vitro immunostimulatory effect. 
This was predicted, as the majority of C-P23 polysaccharides are T cell–independent 
substances except for a small portion (serotype 1), which possess T cell–dependent 
zwitterionic motifs.6,7 Z-P23 augmented the proliferative potential of PBMC in the 
IC group as well as in the control group, and induced significant in vitro synthesis of 
PBMC-soluble IL-2 and IFN-γ but not IL-10 in the IC group versus just an increase 
in IL-10 in the control group. It also augmented the proliferation of CD4+, CD8+, and 
CD21+ PBL selectively in the IC group rather than in the control group. However, 
concanavalin A induced PBMC proliferation mainly in the control group rather than 
in the IC group, increased in vitro synthesis of IL-2, but not IL-10 or IFN-γ, and in-
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Figure 7.  Change in the percentages of peripheral blood lymphocytes (PBL) in relation to 
the levels in the negative control (phosphate buffered saline) of CD4+, CD8+, 
and CD21+ driven by zwitterionized 23-valent pneumococcal polysaccharide 
vaccine (Z-P23) and nonzwitterionized commercial 23-valent pneumococcal 
polysaccharide vaccine (C-P23) in the immunocompromised cancer (IC) group 
versus the healthy control (HC) group.
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creased slightly CD4+, but not CD8+ or CD21+, cells in the control group rather than 
in the IC group.
Unfortunately, no single report was found using or studying zwitterionized pneu-
mococcal polysaccharides to make a comparison with the findings of the present study. 
Nevertheless, the findings of the present study, though this may not correlate to en-
hanced immune function in vivo, suggest that Z-P23 rather than C-P23 exerted an in 
vitro T cell–dependent and/or mitogenic triggering of a robust immune response 
within 48 hours of exposure. Some studies have suggested the presence of a slight 
immunostimulatory effect from C-P23,1,4–7 which was largely boosted by the zwit-
terionization done in this study. Interestingly, unlike concanavalin A, the immuno-
suppression status did not hinder Z-P23 with regard to stimulation of immune cell 
proliferation, cytokine synthesis, or PBL subset proliferation and expansion. Concanava-
lin A, a powerful mitogenic substance, failed to trigger an immune stimulation in 
PBMC in IC patients while it induced a mild immune stimulation in PBMC in health 
control subjects via mild-to-moderate increases in the PBMC proliferative percentage, 
IL-2 level, and percentage of CD4+ cells. Therefore, it could be inferred that the 
immune-triggering pathway of Z-P23 differs from that of concanavalin A. Subsequently, 
it seems that Z-P23 acted as a normalizing immunostimulatory agent for immunosup-
pressed cells. In other words, it served to revert the suppressed immune cells to normal 
status while it did not significantly stimulate the already competent immune cells.
Z-P23 was found to probably stimulate cell-mediated immunity (CMI) more than 
the humeral arm of immunity as the CD8+ and CD4+ cells induction was far higher 
than that of CD21+ cells. The present study also suggested that the immune stimula-
tion of Z-P23 in the IC patients was attributed partially to the synthesis of IL-2 and 
IFN-γ, a T-helper 1 cytokine, rather than IL-10, a T-helper 2 cytokine, as well as 
stimulating CD8+ T cells. Collectively, this provided evidence that Z-P23 stimulates 
mainly T-helper 1 profile of CMI. This might be supported indirectly by other studies 
which stated that children with atopic bronchial asthma from a previous case of 
community-acquired pneumonia, who were administered pneumo-23 vaccine, showed 
a tendency toward a decreased level of serum IgE.23,24 This was either due to the 
complete eradication of the chronic infection of pneumococcal bacteria and/or the 
deviation of the immune system toward T-helper 1, which counteracts the T-helper 2 
atopic arm of immunity.23,24
The present study found that Z-P23 mostly acts as a potent immunostimulator as 
well as an effective T cell–dependent antigen rather than just an antigen, because Z-P23 
induced an immune reaction in IC patients more than healthy controls, which is con-
trary to antigenic stimulation.25 Moreover, the primary immune reaction needs ≥3 days 
to mature,26 while Z-P23–based response was remarkably high in just 48 hours in pa-
tients and control subjects, who had not received prior pneumococcal vaccine.
The mechanism of the observed immunostimulatory action of Z-P23 is not yet 
understood. It might be a combination of T cell–dependent antigen-triggering path-
ways via T-cell receptor, a nonspecific mitogenic signal through bridging of multiple 
costimulatory receptors, or acting as a ligand on TLR. A recent study revealed that 
TLR2 engagement in T-regulatory cells and other T-cell subsets with zwitterionic 
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motifs of polysaccharides modified the functionality and activation state of these cells 
and that most of the effects induced by naturally or chemically derived zwitterion- 
ized polysaccharides may be explained by their TLR2 agonist properties on T cells.8
TLR-mediated signaling primarily activates nuclear factor κB, which plays a critical 
role in the regulation of the expression of groups of genes involved in immune stimu-
lation and inflammatory responses.27,28
Because the current study is novel, this postulated mechanism, or any other mecha-
nism, needs to be researched thoroughly. Limitations of the present study include the 
use of Z-P23 in vitro rather than in vivo in immunocompetent and immunosup-
pressed laboratory animals. Moreover, this study did not use another zwitterionized 
substance for comparison with Z-P23.
COnCLusIOns
Z-P23, but not C-P23, appeared to exert a significant in vitro immunostimulatory effect on 
the isolated PBMC of IC patients more than health control subjects. We recommend con-
ducting thorough studies for scrutinizing the mechanism of action and safety of Z-P23.
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